1991
Midbrain dopamine system electrophysiological functioning: A review and new hypothesis
Bunney B, Chiodo L, Grace A. Midbrain dopamine system electrophysiological functioning: A review and new hypothesis. Synapse 1991, 9: 79-94. PMID: 1821487, DOI: 10.1002/syn.890090202.Peer-Reviewed Original ResearchMechanisms of action of atypical antipsychotic drugs Implications for novel therapeutic strategies for schizophrenia
Deutch A, Moghaddam B, Innis R, Krystal J, Aghajanian G, Bunney B, Charney D. Mechanisms of action of atypical antipsychotic drugs Implications for novel therapeutic strategies for schizophrenia. Schizophrenia Research 1991, 4: 121-156. PMID: 1674882, DOI: 10.1016/0920-9964(91)90030-u.Peer-Reviewed Original ResearchConceptsAtypical antipsychotic drugsAntipsychotic drugsDopamine D2 receptor antagonismD2 receptor antagonismAtypical profileNovel therapeutic strategiesDopamine D2 receptorsMechanism of actionAtypical agentsReceptor antagonismClinical dataD2 receptorsTherapeutic strategiesDrug profileDrugs implicationsMode of actionDrugsAntagonismClozapineRacloprideSerotoninSubtypesSchizophrenia
1986
Does the cholecystokinin antagonist proglumide possess antipsychotic activity?
Innis R, Bunney B, Charney D, Price L, Glazer W, Sternberg D, Rubin A, Heninger G. Does the cholecystokinin antagonist proglumide possess antipsychotic activity? Psychiatry Research 1986, 18: 1-7. PMID: 3737785, DOI: 10.1016/0165-1781(86)90056-9.Peer-Reviewed Original ResearchConceptsPsychosis ratingsPlacebo-controlled studyRole of cholecystokininCentral dopaminergic activityCCK receptor antagonistsPathogenesis of schizophreniaMesocortical neuronsNeuroleptic medicationNeurotransmitter statusReceptor antagonistDopaminergic activityAntipsychotic activitySchizophrenic patientsCholecystokininNegative findingsPreclinical researchProglumidePatientsSchizophreniaPotential reasonsMedicationsPathogenesisAntagonistMidbrainNeuropeptides